<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Med Genet</journal-id><journal-title>BMC Medical Genetics</journal-title><issn pub-type="epub">1471-2350</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1471-2350-10-53</article-id><article-id pub-id-type="pmid">19508727</article-id><article-id pub-id-type="doi">10.1186/1471-2350-10-53</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Mutation analysis of <italic>"Endoglin" </italic>and <italic>"Activin receptor-like kinase" </italic>genes in German patients with hereditary hemorrhagic telangiectasia and the value of rapid genotyping using an allele-specific PCR-technique</article-title></title-group><contrib-group><contrib id="A1" equal-contrib="yes" corresp="yes" contrib-type="author"><name><surname>Haneen</surname><given-names>Sadick</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>haneen.sadick@web.de</email></contrib><contrib id="A2" equal-contrib="yes" contrib-type="author"><name><surname>Johanna</surname><given-names>Hage</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>haneen.sadick@umm.de</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Ulrich</surname><given-names>Goessler</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>ulrich.goessler@hno.ma.uni-heidelberg.de</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Jens</surname><given-names>Stern-Straeter</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>jens.stern-straeter@hno.ma.uni-heidelberg.de</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Frank</surname><given-names>Riedel</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>f_riedel@gmx.de</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Karl</surname><given-names>Hoermann</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>karl.hoermann@umm.de</email></contrib><contrib id="A7" contrib-type="author"><name><surname>Peter</surname><given-names>Bugert</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>peter.bugert@umm.de</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Otolaryngology, Head and Neck Surgery, University Hospital of Mannheim, 68135 Mannheim, Germany</aff><aff id="I2"><label>2</label>Institute of Transfusion Medicine and Immunology, Red Cross Blood Service of Baden-W&#x000fc;rttemberg-Hessen, University of Heidelberg, Medical Faculty of Mannheim, 68135 Mannheim, Germany</aff><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>9</day><month>6</month><year>2009</year></pub-date><volume>10</volume><fpage>53</fpage><lpage>53</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2350/10/53"/><history><date date-type="received"><day>5</day><month>7</month><year>2008</year></date><date date-type="accepted"><day>9</day><month>6</month><year>2009</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2009 Haneen et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>Haneen et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Haneen Sadick haneen.sadick@web.de </dc:author><dc:title> Mutation analysis of "Endoglin" and "Activin receptor-like kinase" genes in German patients with hereditary hemorrhagic telangiectasia and the value of rapid genotyping using an allele-specific PCR-technique </dc:title><dc:date>2009</dc:date><dcterms:bibliographicCitation>BMC Medical Genetics 10(1): 53-. (2009)</dcterms:bibliographicCitation><dc:identifier type="sici">1471-2350(2009)10:1&#x0003c;53&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1471-2350</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>Hereditary hemorrhagic telangiectasia (HHT), also known as Rendu-Osler-Weber syndrome, is an autosomal dominant disorder which is clinically characterised by recurrent epistaxis, mucocutaneous telangiectasia and visceral arteriovenous malformations. Genetic linkage studies identified two genes primarily related to HHT: endoglin (<italic>ENG</italic>) on chromosome 9q33-34 and activin receptor-like kinase1 (<italic>ACVRL1</italic>) on chromosome 12q13. We have screened a total of 41 unselected German patients with the suspected diagnosis of HHT. Mutation analysis for the <italic>ENG </italic>and <italic>ACVRL1 </italic>genes in all patients was performed by PCR amplification. Sequences were then compared to the HHT database <ext-link ext-link-type="uri" xlink:href="http://www.hhtmutation.org"/> sequences of the <italic>ENG </italic>mRNA (accession no. BC014271.2) and the <italic>ACVRL1 </italic>mRNA (accession no. NM000020.1).</p></sec><sec><title>Results</title><p>We identified 15 different mutations in 18 cases by direct sequencing. Among these mutations, one novel <italic>ENG </italic>mutation could be detected which has not yet been described in the literature before. The genotype-phenotype correlation was consistent with a higher frequency of pulmonary arteriovenous malformations in patients with <italic>ENG </italic>mutations than in patients with <italic>ACVRL1 </italic>mutations in our collective.</p></sec><sec><title>Conclusion</title><p>For rapid genotyping of mutations and SNPs (single nucleotide polymorphisms) in <italic>ENG </italic>and <italic>ACVRL1</italic>, allele-specific PCR methods with sequence-specific primers (PCR-SSP) were established and their value analysed.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Hereditary hemorrhagic telangiectasia (HHT, MIM#18730), also known as Rendu-Osler-Weber syndrome, is an autosomal dominant disorder of the fibrovascular tissue. Worldwide, HHT has a prevalence of 1 in 10.000 individuals [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>]. This multi-systemic angiogenic disorder is clinically characterized by severe and recurrent hemorrhages due to epistaxis, mucocutaneous telangiectasia and arteriovenous malformations. Vascular lesions are present in two forms, either as telangiectases on the skin as well as the inner lining of the mouth, nose and gastrointestinal tract (GI-tract) and/or as direct arteriovenous shunts most commonly seen in the lung (<italic>P</italic>AVM), brain (<italic>C</italic>AVM) and liver (<italic>H</italic>AVM) [<xref ref-type="bibr" rid="B3">3</xref>-<xref ref-type="bibr" rid="B9">9</xref>]. Electron microscopy studies on lesion biopsies revealed that dilated postcapillary venules connect directly to arterioles without intervening capillary bed [<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B11">11</xref>]. As a result, these vascular lesions can be the cause for severe complications involving gastrointestinal bleedings, the risk of embolism, stroke and abscesses [<xref ref-type="bibr" rid="B12">12</xref>].</p><p>Till now, HHT can not be cured. The treatment of HHT patients remains symptomatic or has preventive character. The Cura&#x000e7;ao criteria are in clinical use for diagnosis of HHT [<xref ref-type="bibr" rid="B13">13</xref>]. However, the clinical manifestations of HHT can be very heterogeneous, both between families and among members of the same family, making the diagnosis of the disease at times very difficult.</p><p>In the 90s, genetic linkage studies revealed the two major types of disease, HHT1 and HHT2, caused by mutations in the <italic>ENG </italic>(endoglin) and <italic>ACVRL1 </italic>genes. The first locus (HHT type 1) was mapped to chromosome 9q33-34 [<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B15">15</xref>], where the 40 kb endoglin (<italic>ENG</italic>, OMIM 187300) was defined as the affected gene [<xref ref-type="bibr" rid="B16">16</xref>], also associated with a high prevalence of pulmonary arteriovenous malformations [<xref ref-type="bibr" rid="B17">17</xref>]. The second locus (HHT type 2) mapping to chromosome 12q was identified as the 15 kb activin receptor-like kinase-1 gene (<italic>ACVRL1</italic>, OMIM 600376) [<xref ref-type="bibr" rid="B18">18</xref>,<xref ref-type="bibr" rid="B19">19</xref>]. It is characterised by a lower incidence of pulmonary and cerebral arteriovenous malformations than HHT1, but has a higher incidence of liver manifestation [<xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B20">20</xref>]. The corresponding endoglin and ALK-1 proteins are specific endothelial receptors of the transforming growth factor beta superfamily essential for maintaining vascular integrity [<xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B22">22</xref>]. Many mutations have been identified in <italic>ENG </italic>and <italic>ACVRL1 </italic>genes and support the haploinsufficiency model for HHT [<xref ref-type="bibr" rid="B23">23</xref>]. In recent studies, two more genes have been implicated in HHT, which have not yet been identified, the HHT3 gene on chromosome 5 [<xref ref-type="bibr" rid="B24">24</xref>], and the HHT4 gene on chromosome 7 [<xref ref-type="bibr" rid="B25">25</xref>]. In addition, SMAD4 mutations mapping to chromosome 18 have been observed in patients with a combined syndrome of juvenile polyposis and HHT (JPHT) [<xref ref-type="bibr" rid="B26">26</xref>].</p><p>In this study, we report mutational analysis of the two main genes <italic>ENG </italic>and <italic>ACVRL1 </italic>in a German population affected by HHT. We describe a novel mutation in the <italic>ENG </italic>gene in HHT patients which has not been described before. Furthermore, we determine the value of allele-specific PCR for rapid genotyping.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Patients and controls</title><p>Anti-coagulated peripheral blood samples were obtained from 41 patients of German origin with tentative diagnosis of HHT at the Department of ORL, Head and Neck Surgery, University Hospital Mannheim, and from 768 healthy blood donors as a control group from the Institute of Transfusion Medicine and Immunology, Mannheim (Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>). The HHT patients comprised 4 small-sized families (3 persons each) and 29 single cases (Fig. <xref ref-type="fig" rid="F1">1</xref>). Information on the clinical data including the medical history, physical examination and diagnostic screening was obtained in personal interviews with the affected individuals and from their patient records with all the data being documented in an HHT database. According to the Cura&#x000e7;ao criteria, diagnosis for HHT included the presence of three out of four key symptoms: recurrent epistaxis, telangiectasia, hereditary with an affected first degree relative and visceral involvement [<xref ref-type="bibr" rid="B13">13</xref>] (Additional file <xref ref-type="supplementary-material" rid="S2">2</xref>). An informed consent was obtained from each individual and from parents of patients younger than 18 years according to the approval of the Ethic Committee of the University of Mannheim.</p><fig position="float" id="F1"><label>Figure 1</label><caption><p><bold>Pedigree of the four small-sized HHT families</bold>. White square and white circle = unaffected, grey square and grey circle = affected, X = DNA available, # = Pat.-no.</p></caption><graphic xlink:href="1471-2350-10-53-1"/></fig></sec><sec><title>Isolation of DNA</title><p>DNA was extracted from anti-coagulated peripheral blood samples using a commercial DNA isolation kit (QIAamp DNA blood mini kit; Qiagen, Hilden, Germany) according to the standard protocol.</p></sec><sec><title>Sequencing of <italic>ENG </italic>and <italic>ACVRL1 </italic>exons</title><p>All coding exons and flanking intronic sequences of the <italic>ENG </italic>and <italic>ACVRL1 </italic>genes were PCR amplified using primers published previously [<xref ref-type="bibr" rid="B27">27</xref>,<xref ref-type="bibr" rid="B28">28</xref>]. PCR was performed in a total volume of 50 &#x003bc;l including 100 ng DNA, 0.5 &#x003bc;M each primer, 200 &#x003bc;M each dNTP, standard PCR buffer (Qiagen) and 1 U HotStar Taq DNA polymerase (Qiagen). The cycling parameters were as follows: initial denaturation for 15 min at 95&#x000b0;C; 35 cycles with 20 sec. at 94&#x000b0;C, 30 sec. at 60&#x000b0;C and 60 sec. at 72&#x000b0;C; final extension for 5 min at 72&#x000b0;C. After the PCR, products were run on 2% agarose gels. The 15 exons of <italic>ENG </italic>and the 9 exons of <italic>ACVRL1 </italic>were sequenced in 41 patients with HHT using Thermosequenase reagents (GE Healthcare Amersham), IRD700 and IRD800 labelled primers and an automated system (NEN<sup>&#x000ae; </sup>Global IR<sup>2 </sup>DNA Sequencer; LI-COR inc., Lincoln, NE, USA). Sequences were compared to the HHT database <ext-link ext-link-type="uri" xlink:href="http://www.hhtmutation.org"/> sequences of the <italic>ENG </italic>mRNA (accession no. BC014271.2) and the <italic>ACVRL1 </italic>mRNA (accession no. NM000020.1).</p></sec><sec><title>PCR-SSP typing of SNPs</title><p>For rapid genotyping of the mutations and SNPs in <italic>ENG </italic>and <italic>ACVRL1</italic>, allele-specific PCR methods with sequence-specific primers (PCR-SSP) were established. Specific primer sequences and sizes of PCR products are given in Additional file <xref ref-type="supplementary-material" rid="S3">3</xref>. Part of the &#x003b2;-globin locus was amplified as an internal control PCR fragment (540 bp). According to a published PCR-SSP protocol [<xref ref-type="bibr" rid="B29">29</xref>,<xref ref-type="bibr" rid="B30">30</xref>], 20 ng DNA were subjected to 10 &#x003bc;l PCR reactions including 0.5 &#x003bc;M each allele-specific primers, 0.1 &#x003bc;M each internal control primer, standard PCR buffer (Qiagen), 200 &#x003bc;M each dNTP and 0.5 units Taq DNA polymerase (Qiagen). The cycling conditions were: 2 min initial denaturation at 94&#x000b0;C, followed by 10 cycles with 20 s denaturation at 94&#x000b0;C and 1 min annealing/extension at 65&#x000b0;C, followed by 20 cycles with 20 s duration at 94&#x000b0;C, 1 min annealing at 61&#x000b0;C and 30 s extension at 72&#x000b0;C. Amplification products were separated on 2% agarose gels containing 0.5 ng/ml ethidium bromide in a rapid agarose gel electrophoresis (RAGE; Cascade Biologics, Inc., Portland, OR, USA) chamber for 5 min at 25 V/cm. Results were obtained by visual inspection of the gels and were documented by using a UV documentation device with CCD camera (UVP, Inc., Upland, CA, USA).</p></sec></sec><sec><title>Results</title><p>The 15 coding exons of the <italic>ENG </italic>gene and the 9 exons of the <italic>ACVRL1 </italic>gene including flanking intron sequences were PCR amplified and sequenced from 41 patients with HHT. The sequence data were compared to each other and to the <italic>ENG </italic>and <italic>ACVRL1 </italic>sequences published in databases (HHT Mutation Database: <ext-link ext-link-type="uri" xlink:href="http://www.hhtmutation.org"/>). Mutations could be detected in 18 cases (43.9%).</p><sec><title>Sequence analysis of <italic>ENG</italic></title><sec><title><italic>ENG </italic>mutations</title><p>We identified 5 different <italic>ENG </italic>mutations in 6 out of 41 HHT patients. The 5 different <italic>ENG </italic>mutations represented: 1 deletion, 1 insertion, 2 splice site mutations and 1 missense mutation (Additional file <xref ref-type="supplementary-material" rid="S4">4</xref>). In our study, mutation c.816+2T&#x0003e;C was detected in 2 related cases. One novel <italic>ENG </italic>mutation was detected in exon 10 (c.1384insT) causing a frameshift (p.Gln462fs) which has not yet been listed in the HHT gene database before. Altogether, all of the mutations found in <italic>ENG </italic>were detected in exons coding for the extracellular protein-domain. No mutations were detected in the region coding for the intracellular domain (Fig. <xref ref-type="fig" rid="F2">2</xref>).</p><fig position="float" id="F2"><label>Figure 2</label><caption><p><bold>Distribution of mutations in the <italic>ENG </italic>gene</bold>. Novel mutation is given in bold.</p></caption><graphic xlink:href="1471-2350-10-53-2"/></fig></sec><sec><title>Polymorphisms in the <italic>ENG </italic>gene</title><p>The 5 different polymorphisms and their relative frequencies identified in the <italic>ENG </italic>gene are presented in Additional file <xref ref-type="supplementary-material" rid="S5">5</xref>. A previously reported G to A substitution at position 207 of exon 2 (c.207G&#x0003e;A) was observed in 12 out of 41 HHT patients (29.3%). Two patients carried a c.1844C&#x0003e;T polymorphism in exon 13 (4.8%). At position 1029 (c.1029C&#x0003e;T) of exon 8, a C to T change was observed in 7 HHT patients (17%). A c.1347A&#x0003e;G polymorphism in exon 10 and a c.1771G&#x0003e;A polymorphism in exon 13 was observed in one HHT patient (2.4%).</p></sec></sec><sec><title>Sequence analysis of <italic>ACVRL1</italic></title><sec><title><italic>ACVRL1 </italic>mutations</title><p>Ten different <italic>ACVRL1 </italic>mutations could be identified in 12 out of 41 HHT patients, including 2 deletions, 2 insertions, 1 splice site mutation and 5 missense mutations (Additional file <xref ref-type="supplementary-material" rid="S6">6</xref>). The insertion c.144_145insG (p.Ala49fs) was detected in 2 members of the same family, whereas the missense mutation c.1120C&#x0003e;T (p.Arg374Trp) was detected in 2 unrelated cases. Half of the HHT2 associated <italic>ACVRL1 </italic>mutations consisted of single base substitutions, leading to amino acid changes. More than 75% of all <italic>ACVRL1 </italic>mutations were detected in exons coding for the intracellular domain (Fig. <xref ref-type="fig" rid="F3">3</xref>). Especially four out of five missense mutations (80%) were found in the receptor domain or the kinase domain, mainly affecting exon 8. No mutations were detected in the region coding for the transmembrane domain.</p><fig position="float" id="F3"><label>Figure 3</label><caption><p><bold>Distribution of mutations in the <italic>ACVRL1 </italic>gene</bold>.</p></caption><graphic xlink:href="1471-2350-10-53-3"/></fig></sec></sec><sec><title>PCR-SSP typing for <italic>ENG </italic>and <italic>ACVRL1 </italic>mutations</title><p>Further investigation on allele and genotype frequencies focused on the mutations identified in our cohort of HHT patients. PCR-SSP systems could be established for all <italic>ACVRL1 </italic>mutations and all <italic>ENG </italic>mutations. A panel of DNA samples from HHT patients with different mutations was selected on the basis of the sequencing data and was used to validate all 15 PCR-SSP systems. The genotypes were estimated on the basis of the presence or the absence of the allele-specific PCR products (Fig. <xref ref-type="fig" rid="F4">4</xref>). All of the 41 HHT samples were retyped by PCR-SSP and data were compared to sequencing data. We could achieve 100% concordance of data, i.e. DNA samples with mutation revealed a positive PCR signal in the corresponding PCR-SSP system and DNA samples without mutation were negative in all 15 PCR-SSP systems. In addition, the 15 PCR-SSP systems were applied for genotyping of the <italic>ENG </italic>and <italic>ACVRL1 </italic>mutations in 768 healthy blood donor controls. None of the healthy control individuals showed an <italic>ENG </italic>or <italic>ACVRL1 </italic>mutation indicating the specificity of the gene variants for the HHT phenotype.</p><fig position="float" id="F4"><label>Figure 4</label><caption><p><bold>Representative results from PCR-SSP analysis of different <italic>ENG </italic>(A) and <italic>ACVRL1 </italic>(B) mutations</bold>. Three of the 5 PCR-SSP systems for <italic>ENG </italic>mutations and 4 of the 10 PCR-SSP systems for <italic>ACVRL1 </italic>mutations are shown as examples. The specificity of PCR-SSP for the corresponding mutations was given by the absence of the specific PCR product in healthy controls (each lane 1) and presence of the PCR product in the HHT patient (each lane 2). The internal control fragment of 540 bp in size (arrow head) was present in each reaction (or at least where the PCR-SSP product was absent).</p></caption><graphic xlink:href="1471-2350-10-53-4"/></fig></sec><sec><title>Phenotype-Genotype Correlation</title><p>Diagnosis of HHT in an individual required that they met three or more of the following four Cura&#x000e7;ao criteria: 1) spontaneous and recurrent epistaxis, 2) mucocutaneous telangiectasias, 3) organ manifestation with arteriovenous malformations (AVMs) including pulmonary, cerebral, hepatic, gastrointestinal and/or 4) hereditary with a first-degree relative with HHT [<xref ref-type="bibr" rid="B13">13</xref>]. All patients included in this study either met the criteria for manifest clinical diagnosis or suspected clinical diagnosis of HHT with at least three or two criteria present. Altogether, 71% of the patients (29 out of 41) had a manifest HHT diagnosis. All of the patients had as main clinical symptom recurrent epistaxis and a positive family history of HHT, followed by telangiectasias in 65.8% and AVMs of any type in 56% of the cases. Of the 41 patients tested, 18 patients were found to have sequence alterations, with 6 patients showing mutations for <italic>ENG </italic>and 12 patients revealing mutations for <italic>ACVRL1</italic>. The genotype-phenotype correlation of all HHT patients with confirmed mutation is given in Additional file <xref ref-type="supplementary-material" rid="S7">7</xref>.</p></sec></sec><sec><title>Discussion</title><p>Presently, <italic>ENG </italic>(endoglin) on chromosome 9q33-q34 and <italic>ACVRL1 </italic>(activin-receptor-like kinase) on chromosome 12q13 are the two genes primarily implicated in the development of Hereditary Hemorrhagic Telangiectasia (HHT). In literature, frequent mutations in both genes have been detected in different case studies indicating a common occurrence of <italic>ENG </italic>and <italic>ACVRL1 </italic>DNA changes in patients with HHT [<xref ref-type="bibr" rid="B27">27</xref>,<xref ref-type="bibr" rid="B28">28</xref>].</p><p>In a consecutive series of 41 patients, we performed clinical genetic testing for the two major types of disease, HHT1 and HHT2, caused by mutations in the <italic>ENG </italic>and <italic>ACVRL1 </italic>gene sequence for HHT. The series included 29 patients with clinical diagnosis of HHT who met three or more clinical features and 12 patients with suspected diagnosis with two clinical features according to the Cura&#x000e7;ao criteria. The mutation detection rate in our series of 41 German patients was 44%. Based on the Cura&#x000e7;ao criteria, 15 of the 18 patients (83%) with a mutation had a manifest clinical HHT diagnosis, with the remaining 3 patients (17%) fulfilling two criteria. This rate is similar to other studies which have been consistently described in literature [<xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B27">27</xref>,<xref ref-type="bibr" rid="B28">28</xref>]. Most of the mutations were found in the <italic>ACVRL1 </italic>gene with a total of 10 different mutations in 12 HHT patients whereas a total of 5 mutations were identified in the coding sequence of the <italic>ENG </italic>gene in 6 individuals. Most of the <italic>ENG </italic>mutations were widely distributed throughout the gene, not indicating any special hot spot areas within the gene. Out of five detected DNA changes, four mutations had been described previously as mutations in the HHT mutation database or recently been published [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B27">27</xref>,<xref ref-type="bibr" rid="B31">31</xref>-<xref ref-type="bibr" rid="B35">35</xref>]. The alterations included mainly nucleotide substitutions such as missense, splice site and frameshift mutations. In spite of the fact that only a small series of HHT patients was investigated in this study, one novel <italic>ENG </italic>mutation c.1384insT (p.Gln462fs) could be detected which had not been described before in the HHT mutation database. Unlike <italic>ENG</italic>, 50% of the mutations in the ACVRL1 gene were missense substitutions. Similar results had been published by Abdalla et al. who analysed all 123 till then known mutations of <italic>ACVRL1</italic>. In their study overview they could also register more than half (53%) of the mutations in the <italic>ACVRL1 </italic>gene as missense mutations [<xref ref-type="bibr" rid="B36">36</xref>,<xref ref-type="bibr" rid="B37">37</xref>]. As previously described in other HHT families, the frequency of <italic>ACVRL1 </italic>mutations was highest in exon 8 which might be an indicator for mutation hotspots. The other mutations c.144_145insG (p.Ala49fs), c.200G&#x0003e;A (p.Arg67Gln), c.540_541insA (p.Asp181fs), c.673_674delAG (p.Ser225fs), c.696_698delCTC (p.Ser233del), c.1346C&#x0003e;T (p.Pro449Leu) and c.1377+1G&#x0003e;A in <italic>ACVRL1 </italic>were already described by other workgroups, mostly located in the intracellular kinase domain of the gene [<xref ref-type="bibr" rid="B28">28</xref>,<xref ref-type="bibr" rid="B35">35</xref>,<xref ref-type="bibr" rid="B37">37</xref>-<xref ref-type="bibr" rid="B40">40</xref>]. Only two already known mutations could be detected in the extracellular domain of the gene. However, large deletions and insertions in <italic>ENG </italic>and <italic>ACVRL1 </italic>were not analyzed which could explain the low detection rate of mutations in our study compared to other studies described in literature [<xref ref-type="bibr" rid="B28">28</xref>,<xref ref-type="bibr" rid="B32">32</xref>,<xref ref-type="bibr" rid="B36">36</xref>].</p><p>As far as the genotype-phenotype correlation is concerned, most of the pulmonary arteriovenous malformations (<italic>P</italic>AVMs) in our study were detected in HHT patients with mutations for <italic>ENG</italic>. This phenomenon has already been described by previous studies given in literature, stating that mutations of <italic>ENG </italic>are mainly observed in HHT type 1 with an incidence of up to 40% for <italic>P</italic>AVMs, whereas mutations of <italic>ALK1 </italic>are primarily observed in HHT type 2 with an incidence of only 14% for <italic>P</italic>AVMs, which clinically distinguishes these two types of mutation [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B28">28</xref>,<xref ref-type="bibr" rid="B36">36</xref>]. Liver manifestations were more frequent in patients with <italic>ACVRL1 </italic>mutations, whereas manifestations of the skin and the GI-tract were seen equally distributed amongst HHT patients with <italic>ENG </italic>and <italic>ACVRL1 </italic>mutations.</p><p>Many studies report a mutation detection rate of up to 92% [<xref ref-type="bibr" rid="B27">27</xref>,<xref ref-type="bibr" rid="B28">28</xref>,<xref ref-type="bibr" rid="B33">33</xref>]. However, in our study we were able to identify only 43.9% of disease-causing mutations in a series of 41 HHT patients. The difference in sensitivity may result from several factors, including a very heterogeneous cohort of patients in terms of locations and initial physician involved, and because patients with only 2 Cura&#x000e7;ao criteria were included in the study. In addition, only <italic>ENG </italic>and <italic>ACVRL1 </italic>genes were screened for mutations, but in some cases, mutations in SMAD4, HHT3 and HHT4 loci may be responsible for the clinical symptoms [<xref ref-type="bibr" rid="B24">24</xref>-<xref ref-type="bibr" rid="B26">26</xref>].</p><p>In daily clinical routine, the diagnosis of HHT is primarily based on the clinical findings according to the Cura&#x000e7;ao criteria. Nevertheless, in many cases clinical diagnostic is at times very difficult due to the heterogeneous outcome and manifestation of the disease. This fact asks for additional diagnostic tools which facilitate the daily clinical work. Already in the past, many studies could show that the molecular characterization of HHT enables to predict the diagnosis before the manifestation of clinical symptoms. The results of the study reflect the very high and heterogenic distribution and allocation of mutations in HHT. With an allele-specific PCR technique (PCR-SSP) we could establish a diagnostic testing device for rapid genotyping of mutations. The exon sequencing of <italic>ENG </italic>and <italic>ACVRL1 </italic>confirmed the previously described polymorphisms and outlined one novel mutation Gln462fs in exon 10 of <italic>ENG </italic>gene. The PCR-SSP technique can easily be performed with standard laboratory equipment and may help to minimize costs for genetic testing in the routine diagnosis of family members of HHT patients with known mutations.</p></sec><sec><title>Conclusion</title><p>In summary, this study is a further contribution to the determination of already known <italic>ENG </italic>and <italic>ACVRL1 </italic>mutations as well as the detection of one novel <italic>ENG </italic>mutation in HHT. Next to the Cura&#x000e7;ao criteria, genetic analysis certainly contributes as an essential tool to a reliable diagnosis of clinically affected HHT patients and clinically un-symptomatic HHT patients, thus helping to take early preventive measures even before the occurrence of first clinical symptoms. The PCR-SSP technique could facilitate this high task of genetic analysis in routine HHT diagnostics and underlines the importance of using molecular diagnosis for early identification of individuals carrying mutations and being at risk of vascular complications.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>All the authors have read and approved the final manuscript. A large part of the mutational analysis was done by HS, JH under the supervision of PB. The rest of the mutational analysis was done by UG, JS, KH completing the analysis of mutations. Bank data collection, writing of the manuscript and the direction of all the work was done under HS, the main author.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2350/10/53/prepub"/></p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="S1"><caption><title>Additional file 1</title><p><bold>Table 1</bold>. Overview on the detailed clinical data of all HHT patients.</p></caption><media xlink:href="1471-2350-10-53-S1.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S2"><caption><title>Additional file 2</title><p><bold>Table 2</bold>. Diagnostic criteria according to the Cura&#x000e7;ao criteria for the diagnosis of HHT.</p></caption><media xlink:href="1471-2350-10-53-S2.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S3"><caption><title>Additional file 3</title><p><bold>Table 3</bold>. Primers used in PCR-SSP genotyping for mutations in the <italic>ENG </italic>and <italic>ACVRL1 </italic>genes.</p></caption><media xlink:href="1471-2350-10-53-S3.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S4"><caption><title>Additional file 4</title><p><bold>Table 4</bold>. Summary of mutations identified in the <italic>ENG </italic>gene.</p></caption><media xlink:href="1471-2350-10-53-S4.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S5"><caption><title>Additional file 5</title><p><bold>Table 5</bold>. Polymorphisms in <italic>ENG</italic>.</p></caption><media xlink:href="1471-2350-10-53-S5.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S6"><caption><title>Additional file 6</title><p><bold>Table 6</bold>. Summary of mutations identified in the <italic>ACVRL1 </italic>gene.</p></caption><media xlink:href="1471-2350-10-53-S6.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S7"><caption><title>Additional file 7</title><p><bold>Table 7</bold>. Genotype-phenotype correlation in HHT patients with confirmed mutation.</p></caption><media xlink:href="1471-2350-10-53-S7.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for file</p></caption></media></supplementary-material></sec></body><back><ack><sec><title>Acknowledgements</title><p>We are indebted to the patients and their families and relatives for their participation. We would like to thank Petra Prohaska and Gabi Rink for excellent technical assistance.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guttmacher</surname><given-names>AE</given-names></name><name><surname>Marchuk</surname><given-names>DA</given-names></name><name><surname>White</surname><given-names>RI</given-names><suffix>Jr</suffix></name></person-group><article-title>Hereditary hemorrhagic telangiectasia</article-title><source>N Engl J Med</source><year>1995</year><volume>333</volume><fpage>918</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">7666879</pub-id><pub-id pub-id-type="doi">10.1056/NEJM199510053331407</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Abdalla</surname><given-names>SA</given-names></name><name><surname>Cymerman</surname><given-names>U</given-names></name><name><surname>Rushlow</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>N</given-names></name><name><surname>Stoeber</surname><given-names>GP</given-names></name><name><surname>Lemire</surname><given-names>EG</given-names></name><name><surname>Letarte</surname><given-names>M</given-names></name></person-group><article-title>Novel mutations and polymorphisms in genes causing hereditary hemorrhagic telangiectasia</article-title><source>Hum Mutat</source><year>2005</year><volume>25</volume><fpage>320</fpage><lpage>1</lpage><pub-id pub-id-type="pmid">15712271</pub-id><pub-id pub-id-type="doi">10.1002/humu.9312</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kjeldsen</surname><given-names>A</given-names></name><name><surname>Kjeldsen</surname><given-names>J</given-names></name></person-group><article-title>Gastrointestinal bleeding in patients with hereditary hemorrhagic telangiectasia</article-title><source>Am J Gastroenterol</source><year>2000</year><volume>95</volume><fpage>415</fpage><lpage>418</lpage><pub-id pub-id-type="pmid">10685743</pub-id><pub-id pub-id-type="doi">10.1111/j.1572-0241.2000.01792.x</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reilly</surname><given-names>PJ</given-names></name><name><surname>Nostrant</surname><given-names>TT</given-names></name></person-group><article-title>Clinical manifestations of hereditary hemorrhagic telangiectasia</article-title><source>Am J Gastroenterol</source><year>1984</year><volume>79</volume><fpage>363</fpage><lpage>367</lpage><pub-id pub-id-type="pmid">6609633</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kjeldsen</surname><given-names>AD</given-names></name><name><surname>Oxh&#x000f8;j</surname><given-names>H</given-names></name><name><surname>Andersen</surname><given-names>PE</given-names></name><name><surname>Green</surname><given-names>A</given-names></name><name><surname>Vase</surname><given-names>P</given-names></name></person-group><article-title>Prevalence of pulmonary arteriovenous malformations (PAVMs) and occurrence of neurologic symptoms in patients with hereditary haemorrhagic telangiectasia (HHT)</article-title><source>J Int Med</source><year>2000</year><volume>248</volume><fpage>255</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2796.2000.00725.x</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shovlin</surname><given-names>CL</given-names></name><name><surname>Letarte</surname><given-names>M</given-names></name></person-group><article-title>Hereditary haemorrhagic telangiectasia and pulmonary arteriovenous malformations: issues in clinical management and review of pathogenic mechanisms</article-title><source>Thorax</source><year>1999</year><volume>54</volume><fpage>714</fpage><lpage>729</lpage><pub-id pub-id-type="pmid">10413726</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bernard</surname><given-names>G</given-names></name><name><surname>Mion</surname><given-names>F</given-names></name><name><surname>Henry</surname><given-names>L</given-names></name><name><surname>Plauchu</surname><given-names>H</given-names></name><name><surname>Paliard</surname><given-names>P</given-names></name></person-group><article-title>Hepatic involvement in hereditary haemorrhagic telangiectasia: clinical, radiological, and hemodynamic studies of 11 cases</article-title><source>Gastroenterology</source><year>1993</year><volume>105</volume><fpage>482</fpage><lpage>487</lpage><pub-id pub-id-type="pmid">8335203</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Tsao</surname><given-names>G</given-names></name><name><surname>Korzenik</surname><given-names>JR</given-names></name><name><surname>Young</surname><given-names>L</given-names></name><name><surname>Henderson</surname><given-names>KJ</given-names></name><name><surname>Jain</surname><given-names>D</given-names></name><name><surname>Byrd</surname><given-names>B</given-names></name><name><surname>Pollak</surname><given-names>JS</given-names></name><name><surname>White</surname><given-names>RI</given-names><suffix>Jr</suffix></name></person-group><article-title>Liver disease in patients with hereditary hemorrhagic telangiectasia</article-title><source>N Engl J Med</source><year>2000</year><volume>343</volume><fpage>931</fpage><lpage>936</lpage><pub-id pub-id-type="pmid">11006369</pub-id><pub-id pub-id-type="doi">10.1056/NEJM200009283431305</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sadick</surname><given-names>H</given-names></name><name><surname>Sadick</surname><given-names>M</given-names></name><name><surname>G&#x000f6;tte</surname><given-names>K</given-names></name><name><surname>Naim</surname><given-names>R</given-names></name><name><surname>Riedel</surname><given-names>F</given-names></name><name><surname>Bran</surname><given-names>G</given-names></name><name><surname>H&#x000f6;rmann</surname><given-names>K</given-names></name></person-group><article-title>Hereditary hemorrhagic telangiectasia: an update on clinical manifestations and diagnostic measures</article-title><source>Wien Klin Wochenschr</source><year>2006</year><volume>118</volume><fpage>72</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">16703249</pub-id><pub-id pub-id-type="doi">10.1007/s00508-006-0561-x</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Braverman</surname><given-names>IM</given-names></name><name><surname>Keh</surname><given-names>A</given-names></name><name><surname>Jacobson</surname><given-names>BS</given-names></name></person-group><article-title>Ultrastructure and three-dimensional organization of the teleangiectases of hereditary hemorrhagic teleangiectasia</article-title><source>J Invest Dermatol</source><year>1990</year><volume>95</volume><fpage>422</fpage><lpage>427</lpage><pub-id pub-id-type="pmid">2212727</pub-id><pub-id pub-id-type="doi">10.1111/1523-1747.ep12555569</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jahnke</surname><given-names>V</given-names></name></person-group><article-title>Ultrastructure of hereditary hemorrhagic telangiectasia</article-title><source>Arch Otolaryngol Head and Neck Surg</source><year>1970</year><volume>91</volume><fpage>262</fpage><lpage>265</lpage></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>RI</given-names><suffix>Jr</suffix></name></person-group><article-title>Pulmonary arteriovenous malformations: how do we diagnose them and why is it important to do so?</article-title><source>Radiology</source><year>1992</year><volume>182</volume><fpage>633</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">1535872</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shovlin</surname><given-names>CL</given-names></name><name><surname>Guttmacher</surname><given-names>AE</given-names></name><name><surname>Buscarini</surname><given-names>E</given-names></name><name><surname>Faughnan</surname><given-names>ME</given-names></name><name><surname>Hyland</surname><given-names>RH</given-names></name><name><surname>Westermann</surname><given-names>CJ</given-names></name><name><surname>Kjeldsen</surname><given-names>AD</given-names></name><name><surname>Plauchu</surname><given-names>H</given-names></name></person-group><article-title>Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome)</article-title><source>Am J Med Genet</source><year>2000</year><volume>91</volume><fpage>66</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">10751092</pub-id><pub-id pub-id-type="doi">10.1002/(SICI)1096-8628(20000306)91:1&#x0003c;66::AID-AJMG12&#x0003e;3.0.CO;2-P</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McDonald</surname><given-names>MT</given-names></name><name><surname>Papenberg</surname><given-names>KA</given-names></name><name><surname>Ghosh</surname><given-names>S</given-names></name><name><surname>Glatfelter</surname><given-names>AA</given-names></name><name><surname>Biesecker</surname><given-names>BB</given-names></name><name><surname>Helmbold</surname><given-names>EA</given-names></name><name><surname>Markel</surname><given-names>DS</given-names></name><name><surname>Zolotor</surname><given-names>A</given-names></name><name><surname>McKinnon</surname><given-names>WC</given-names></name><name><surname>Vanderstoep</surname><given-names>JL</given-names></name><name><surname>Jackson</surname><given-names>CE</given-names></name><name><surname>Iannuzzi</surname><given-names>M</given-names></name><name><surname>Collins</surname><given-names>FS</given-names></name><name><surname>Boehnke</surname><given-names>M</given-names></name><name><surname>Porteous</surname><given-names>ME</given-names></name><name><surname>Guttmacher</surname><given-names>AE</given-names></name><name><surname>Marchuk</surname><given-names>DA</given-names></name></person-group><article-title>A disease locus for hereditary haemorrhagic telangiectasia maps to chromosome 9q33-34</article-title><source>Nat Genet</source><year>1994</year><volume>6</volume><fpage>197</fpage><lpage>204</lpage><pub-id pub-id-type="pmid">8162075</pub-id><pub-id pub-id-type="doi">10.1038/ng0294-197</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shovlin</surname><given-names>CL</given-names></name><name><surname>Hughes</surname><given-names>JM</given-names></name><name><surname>Tuddenham</surname><given-names>EG</given-names></name><name><surname>Temperley</surname><given-names>I</given-names></name><name><surname>Perembelon</surname><given-names>YF</given-names></name><name><surname>Scott</surname><given-names>J</given-names></name><name><surname>Seidman</surname><given-names>CE</given-names></name><name><surname>Seidman</surname><given-names>JG</given-names></name></person-group><article-title>A gene for hereditary haemorrhagic telangiectasia maps to chromosome 9q3</article-title><source>Nat Genet</source><year>1994</year><volume>6</volume><fpage>205</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">8162076</pub-id><pub-id pub-id-type="doi">10.1038/ng0294-205</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McAllister</surname><given-names>KA</given-names></name><name><surname>Grogg</surname><given-names>KM</given-names></name><name><surname>Johnson</surname><given-names>DW</given-names></name><name><surname>Gallione</surname><given-names>CJ</given-names></name><name><surname>Baldwin</surname><given-names>MA</given-names></name><name><surname>Jackson</surname><given-names>CE</given-names></name><name><surname>Helmbold</surname><given-names>EA</given-names></name><name><surname>Markel</surname><given-names>DS</given-names></name><name><surname>McKinnon</surname><given-names>WC</given-names></name><name><surname>Murrell</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1</article-title><source>Nat Genet</source><year>1994</year><volume>8</volume><fpage>345</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">7894484</pub-id><pub-id pub-id-type="doi">10.1038/ng1294-345</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Letteboer</surname><given-names>TG</given-names></name><name><surname>Mager</surname><given-names>JJ</given-names></name><name><surname>Snijder</surname><given-names>RJ</given-names></name><name><surname>Koeleman</surname><given-names>BP</given-names></name><name><surname>Lindhout</surname><given-names>D</given-names></name><name><surname>Ploos van Amstel</surname><given-names>JK</given-names></name><name><surname>Westermann</surname><given-names>CJ</given-names></name></person-group><article-title>Genotype-phenotype relationship in hereditary haemorrhagic telangiectasia</article-title><source>J Med Genet</source><year>2006</year><volume>43</volume><fpage>371</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">16155196</pub-id><pub-id pub-id-type="doi">10.1136/jmg.2005.035451</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Berg</surname><given-names>JN</given-names></name><name><surname>Gallione</surname><given-names>CJ</given-names></name><name><surname>Stenzel</surname><given-names>TT</given-names></name><name><surname>Johnson</surname><given-names>DW</given-names></name><name><surname>Allen</surname><given-names>WP</given-names></name><name><surname>Schwartz</surname><given-names>CE</given-names></name><name><surname>Jackson</surname><given-names>CE</given-names></name><name><surname>Porteous</surname><given-names>ME</given-names></name><name><surname>Marchuk</surname><given-names>DA</given-names></name><collab>The activin receptor-like kinase 1 gene</collab></person-group><article-title>genomic structure and mutations in hereditary hemorrhagic telangiectasia type 2</article-title><source>Am J Hum Genet</source><year>1997</year><volume>61</volume><fpage>60</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">9245985</pub-id><pub-id pub-id-type="doi">10.1086/513903</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>DW</given-names></name><name><surname>Berg</surname><given-names>JN</given-names></name><name><surname>Baldwin</surname><given-names>MA</given-names></name><name><surname>Gallione</surname><given-names>CJ</given-names></name><name><surname>Marondel</surname><given-names>I</given-names></name><name><surname>Yoon</surname><given-names>SJ</given-names></name><name><surname>Stenzel</surname><given-names>TT</given-names></name><name><surname>Speer</surname><given-names>M</given-names></name><name><surname>Pericak-Vance</surname><given-names>MA</given-names></name><name><surname>Diamond</surname><given-names>A</given-names></name><name><surname>Guttmacher</surname><given-names>AE</given-names></name><name><surname>Jackson</surname><given-names>CE</given-names></name><name><surname>Attisano</surname><given-names>L</given-names></name><name><surname>Kucherlapati</surname><given-names>R</given-names></name><name><surname>Porteous</surname><given-names>ME</given-names></name><name><surname>Marchuk</surname><given-names>DA</given-names></name></person-group><article-title>Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2</article-title><source>Nat Genet</source><year>1996</year><volume>13</volume><fpage>189</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">8640225</pub-id><pub-id pub-id-type="doi">10.1038/ng0696-189</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kuehl</surname><given-names>HK</given-names></name><name><surname>Caselitz</surname><given-names>M</given-names></name><name><surname>Hasenkamp</surname><given-names>S</given-names></name><name><surname>Wagner</surname><given-names>S</given-names></name><name><surname>El-Harith</surname><given-names>el-HA</given-names></name><name><surname>Manns</surname><given-names>MP</given-names></name><name><surname>Stuhrmann</surname><given-names>M</given-names></name></person-group><article-title>Hepatic manifestation is associated with ALK1 in hereditary hemorrhagic telangiectasia: identification of five novel ALK1 and one novel ENG mutations</article-title><source>Hum Mutat</source><year>2005</year><volume>25</volume><fpage>320</fpage><pub-id pub-id-type="pmid">15712270</pub-id><pub-id pub-id-type="doi">10.1002/humu.9311</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arthur</surname><given-names>HM</given-names></name><name><surname>Ure</surname><given-names>J</given-names></name><name><surname>Smith</surname><given-names>AJ</given-names></name><name><surname>Renforth</surname><given-names>G</given-names></name><name><surname>Wilson</surname><given-names>DI</given-names></name><name><surname>Torsney</surname><given-names>E</given-names></name><name><surname>Charlton</surname><given-names>R</given-names></name><name><surname>Parums</surname><given-names>DV</given-names></name><name><surname>Jowett</surname><given-names>T</given-names></name><name><surname>Marchuk</surname><given-names>DA</given-names></name><name><surname>Burn</surname><given-names>J</given-names></name><name><surname>Diamond</surname><given-names>AG</given-names></name></person-group><article-title>Endoglin, an ancillary TGFbeta receptor, is required for extraembryonic angiogenesis and plays a key role in heart development</article-title><source>Dev Biol</source><year>2000</year><volume>217</volume><fpage>42</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">10625534</pub-id><pub-id pub-id-type="doi">10.1006/dbio.1999.9534</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oh</surname><given-names>SP</given-names></name><name><surname>Seki</surname><given-names>T</given-names></name><name><surname>Goss</surname><given-names>KA</given-names></name><name><surname>Imamura</surname><given-names>T</given-names></name><name><surname>Yi</surname><given-names>Y</given-names></name><name><surname>Donahoe</surname><given-names>PK</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Miyazono</surname><given-names>K</given-names></name><name><surname>ten Dijke</surname><given-names>P</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>E</given-names></name></person-group><article-title>Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis</article-title><source>Proc Natl Acad Sci USA</source><year>2000</year><volume>97</volume><fpage>2626</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">10716993</pub-id><pub-id pub-id-type="doi">10.1073/pnas.97.6.2626</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pece-Barbara</surname><given-names>N</given-names></name><name><surname>Cymerman</surname><given-names>U</given-names></name><name><surname>Vera</surname><given-names>S</given-names></name><name><surname>Marchuk</surname><given-names>DA</given-names></name><name><surname>Letarte</surname><given-names>M</given-names></name></person-group><article-title>Expression analysis of four endoglin missense mutations suggests that haploinsufficiency is the predominant mechanism for hereditary hemorrhagic telangiectasia type 1</article-title><source>Hum Mol Genet</source><year>1999</year><volume>8</volume><fpage>2171</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">10545596</pub-id><pub-id pub-id-type="doi">10.1093/hmg/8.12.2171</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cole</surname><given-names>SG</given-names></name><name><surname>Begbie</surname><given-names>ME</given-names></name><name><surname>Wallace</surname><given-names>GM</given-names></name><name><surname>Shovlin</surname><given-names>CL</given-names></name></person-group><article-title>A new locus for hereditary haemorrhagic telangiectasia (HHT3) maps to chromosome 5</article-title><source>J Med Genet</source><year>2005</year><volume>42</volume><fpage>577</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">15994879</pub-id><pub-id pub-id-type="doi">10.1136/jmg.2004.028712</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bayrak-Toydemir</surname><given-names>P</given-names></name><name><surname>McDonald</surname><given-names>J</given-names></name><name><surname>Akarsu</surname><given-names>N</given-names></name><name><surname>Toydemir</surname><given-names>RM</given-names></name><name><surname>Calderon</surname><given-names>F</given-names></name><name><surname>Tuncali</surname><given-names>T</given-names></name><name><surname>Tang</surname><given-names>W</given-names></name><name><surname>Miller</surname><given-names>F</given-names></name><name><surname>Mao</surname><given-names>R</given-names></name></person-group><article-title>A fourth locus for hereditary hemorrhagic telangiectasia maps to chromosome 7</article-title><source>Am J Med Genet A</source><year>2006</year><volume>140</volume><fpage>2155</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">16969873</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gallione</surname><given-names>CJ</given-names></name><name><surname>Repetto</surname><given-names>GM</given-names></name><name><surname>Legius</surname><given-names>E</given-names></name><name><surname>Rustgi</surname><given-names>AK</given-names></name><name><surname>Schelley</surname><given-names>SL</given-names></name><name><surname>Tejpar</surname><given-names>S</given-names></name><name><surname>Mitchell</surname><given-names>G</given-names></name><name><surname>Drouin</surname><given-names>E</given-names></name><name><surname>Westermann</surname><given-names>CJ</given-names></name><name><surname>Marchuk</surname><given-names>DA</given-names></name></person-group><article-title>A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4)</article-title><source>Lancet</source><year>2004</year><volume>363</volume><fpage>852</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">15031030</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(04)15732-2</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Abdalla</surname><given-names>SA</given-names></name><name><surname>Letarte</surname><given-names>M</given-names></name></person-group><article-title>Hereditary haemorrhagic telangiectasia: current views on genetics and mechanisms of disease</article-title><source>J Med Genet</source><year>2006</year><volume>43</volume><fpage>97</fpage><lpage>110</lpage><pub-id pub-id-type="pmid">15879500</pub-id><pub-id pub-id-type="doi">10.1136/jmg.2005.030833</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schulte</surname><given-names>C</given-names></name><name><surname>Geisthoff</surname><given-names>U</given-names></name><name><surname>Lux</surname><given-names>A</given-names></name><name><surname>Kupka</surname><given-names>S</given-names></name><name><surname>Zenner</surname><given-names>HP</given-names></name><name><surname>Blin</surname><given-names>N</given-names></name><name><surname>Pfister</surname><given-names>M</given-names></name></person-group><article-title>High frequency of ENG and ALK1/ACVRL1 mutations in German HHT patients</article-title><source>Hum Mutat</source><year>2005</year><volume>25</volume><fpage>595</fpage><pub-id pub-id-type="pmid">15880681</pub-id><pub-id pub-id-type="doi">10.1002/humu.9345</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bugert</surname><given-names>P</given-names></name><name><surname>Hoffmann</surname><given-names>MM</given-names></name><name><surname>Winkelmann</surname><given-names>BR</given-names></name><name><surname>Vosberg</surname><given-names>M</given-names></name><name><surname>Jahn</surname><given-names>J</given-names></name><name><surname>Entelmann</surname><given-names>M</given-names></name><name><surname>Katus</surname><given-names>HA</given-names></name><name><surname>M&#x000e4;rz</surname><given-names>W</given-names></name><name><surname>Mansmann</surname><given-names>U</given-names></name><name><surname>Boehm</surname><given-names>BO</given-names></name><name><surname>Goerg</surname><given-names>S</given-names></name><name><surname>Kl&#x000fc;ter</surname><given-names>H</given-names></name></person-group><article-title>The variable number of tandem repeat polymorphism in the P-selectin glycoprotein ligand-1 gene is not associated with coronary heart disease</article-title><source>J Mol Med</source><year>2003</year><volume>81</volume><fpage>495</fpage><lpage>501</lpage><pub-id pub-id-type="pmid">12879153</pub-id><pub-id pub-id-type="doi">10.1007/s00109-003-0459-2</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bugert</surname><given-names>P</given-names></name><name><surname>Lese</surname><given-names>A</given-names></name><name><surname>Meckies</surname><given-names>J</given-names></name><name><surname>Zieger</surname><given-names>W</given-names></name><name><surname>Eichler</surname><given-names>H</given-names></name><name><surname>Kl&#x000fc;ter</surname><given-names>H</given-names></name></person-group><article-title>Optimized sensitivity of allele-specific PCR for prenatal typing of human platelet alloantigen single nucleotide polymorphisms</article-title><source>Biotechniques</source><year>2003</year><volume>35</volume><fpage>170</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">12866418</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bossler</surname><given-names>AD</given-names></name><name><surname>Richards</surname><given-names>J</given-names></name><name><surname>George</surname><given-names>C</given-names></name><name><surname>Godmilow</surname><given-names>L</given-names></name><name><surname>Ganguly</surname><given-names>A</given-names></name></person-group><article-title>Novel mutations in ENG and ACVRL1 identified in a series of 200 individuals undergoing clinical genetic testing for hereditary hemorrhagic telangiectasia HHT): correlation of genotype with phenotype</article-title><source>Hum Mutat</source><year>2006</year><volume>27</volume><fpage>667</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">16752392</pub-id><pub-id pub-id-type="doi">10.1002/humu.20342</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lesca</surname><given-names>G</given-names></name><name><surname>Burnichon</surname><given-names>N</given-names></name><name><surname>Raux</surname><given-names>G</given-names></name><name><surname>Tosi</surname><given-names>M</given-names></name><name><surname>Pinson</surname><given-names>S</given-names></name><name><surname>Marion</surname><given-names>MJ</given-names></name><name><surname>Babin</surname><given-names>E</given-names></name><name><surname>Gilbert-Dussardier</surname><given-names>B</given-names></name><name><surname>Rivi&#x000e8;re</surname><given-names>S</given-names></name><name><surname>Goizet</surname><given-names>C</given-names></name><name><surname>Faivre</surname><given-names>L</given-names></name><name><surname>Plauchu</surname><given-names>H</given-names></name><name><surname>Fr&#x000e9;bourg</surname><given-names>T</given-names></name><name><surname>Calender</surname><given-names>A</given-names></name><name><surname>Giraud</surname><given-names>S</given-names></name><collab>French Rendu-Osler Network</collab></person-group><article-title>Distribution of ENG and ACVRL1 (ALK1) mutations in French HHT patients</article-title><source>Hum Mutat</source><year>2006</year><volume>27</volume><fpage>598</fpage><pub-id pub-id-type="pmid">16705692</pub-id><pub-id pub-id-type="doi">10.1002/humu.9421</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lesca</surname><given-names>G</given-names></name><name><surname>Olivieri</surname><given-names>C</given-names></name><name><surname>Burnichon</surname><given-names>N</given-names></name><name><surname>Pagella</surname><given-names>F</given-names></name><name><surname>Carette</surname><given-names>MF</given-names></name><name><surname>Gilbert-Dussardier</surname><given-names>B</given-names></name><name><surname>Goizet</surname><given-names>C</given-names></name><name><surname>Roume</surname><given-names>J</given-names></name><name><surname>Rabilloud</surname><given-names>M</given-names></name><name><surname>Saurin</surname><given-names>JC</given-names></name><name><surname>Cottin</surname><given-names>V</given-names></name><name><surname>Honnorat</surname><given-names>J</given-names></name><name><surname>Coulet</surname><given-names>F</given-names></name><name><surname>Giraud</surname><given-names>S</given-names></name><name><surname>Calender</surname><given-names>A</given-names></name><name><surname>Danesino</surname><given-names>C</given-names></name><name><surname>Buscarini</surname><given-names>E</given-names></name><name><surname>Plauchu</surname><given-names>H</given-names></name><name><surname>French-Italian-Rendu-Osler</surname><given-names>Network</given-names></name></person-group><article-title>Genotype-phenotype correlations in hereditary hemorrhagic telangiectasia: data from the French-Italian HHT network</article-title><source>Genet Med</source><year>2007</year><volume>9</volume><fpage>14</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">17224686</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fernandez-L</surname><given-names>A</given-names></name><name><surname>Sanz-Rodriguez</surname><given-names>F</given-names></name><name><surname>Zarrabeitia</surname><given-names>R</given-names></name><name><surname>Perez-Molino</surname><given-names>A</given-names></name><name><surname>Morales</surname><given-names>C</given-names></name><name><surname>Restrepo</surname><given-names>CM</given-names></name><name><surname>Ramirez</surname><given-names>JR</given-names></name><name><surname>Coto</surname><given-names>E</given-names></name><name><surname>Lenato</surname><given-names>GM</given-names></name><name><surname>Bernabeu</surname><given-names>C</given-names></name><name><surname>Botella</surname><given-names>LM</given-names></name></person-group><article-title>Mutation study of Spanish patients with hereditary hemorrhagic telangiectasia and expression analysis of Endoglin and ALK1</article-title><source>Hum Mutat</source><year>2006</year><volume>27</volume><fpage>295</fpage><pub-id pub-id-type="pmid">16470589</pub-id><pub-id pub-id-type="doi">10.1002/humu.9413</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fontalba</surname><given-names>A</given-names></name><name><surname>Fernandez-L</surname><given-names>A</given-names></name><name><surname>Garc&#x000ed;a-Alegria</surname><given-names>E</given-names></name><name><surname>Albi&#x000f1;ana</surname><given-names>V</given-names></name><name><surname>Garrido-Martin</surname><given-names>EM</given-names></name><name><surname>Blanco</surname><given-names>FJ</given-names></name><name><surname>Zarrabeitia</surname><given-names>R</given-names></name><name><surname>Perez-Molino</surname><given-names>A</given-names></name><name><surname>Bernabeu-Herrero</surname><given-names>ME</given-names></name><name><surname>Ojeda</surname><given-names>ML</given-names></name><name><surname>Fernandez-Luna</surname><given-names>JL</given-names></name><name><surname>Bernabeu</surname><given-names>C</given-names></name><name><surname>Botella</surname><given-names>LM</given-names></name></person-group><article-title>Mutation study of Spanish patients with hereditary hemorrhagic telangiectasia</article-title><source>BMC Med Genet</source><year>2008</year><volume>9</volume><fpage>75</fpage><pub-id pub-id-type="pmid">18673552</pub-id><pub-id pub-id-type="doi">10.1186/1471-2350-9-75</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wehner</surname><given-names>LE</given-names></name><name><surname>Folz</surname><given-names>BJ</given-names></name><name><surname>Argyriou</surname><given-names>L</given-names></name><name><surname>Twelkemeyer</surname><given-names>S</given-names></name><name><surname>Teske</surname><given-names>U</given-names></name><name><surname>Geisthoff</surname><given-names>UW</given-names></name><name><surname>Werner</surname><given-names>JA</given-names></name><name><surname>Engel</surname><given-names>W</given-names></name><name><surname>Nayernia</surname><given-names>K</given-names></name></person-group><article-title>Mutation analysis in hereditary haemorrhagic telangiectasia in Germany reveals 11 novel ENG and 12 novel ACVRL1/ALK1 mutations</article-title><source>Clin Genet</source><year>2006</year><volume>69</volume><fpage>239</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">16542389</pub-id><pub-id pub-id-type="doi">10.1111/j.1399-0004.2006.00574.x</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Abdalla</surname><given-names>SA</given-names></name><name><surname>Letarte</surname><given-names>M</given-names></name></person-group><article-title>Hereditary haemorrhagic telangiectasia: current views on genetics and mechanisms of disease</article-title><source>J Med Genet</source><year>2006</year><volume>43</volume><fpage>97</fpage><lpage>110</lpage><pub-id pub-id-type="pmid">15879500</pub-id><pub-id pub-id-type="doi">10.1136/jmg.2005.030833</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Klaus</surname><given-names>DJ</given-names></name><name><surname>Gallione</surname><given-names>CJ</given-names></name><name><surname>Anthony</surname><given-names>K</given-names></name><name><surname>Yeh</surname><given-names>EY</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Lux</surname><given-names>A</given-names></name><name><surname>Johnson</surname><given-names>DW</given-names></name><name><surname>Marchuk</surname><given-names>DA</given-names></name></person-group><article-title>Novel missense and frameshift mutations in the activin receptor-like kinase-1 gene in hereditary hemorrhagic telangiectasia. Mutations in brief no. 164</article-title><source>Hum Mutat</source><year>1998</year><volume>12</volume><fpage>137</fpage><pub-id pub-id-type="pmid">10694922</pub-id><pub-id pub-id-type="doi">10.1002/(SICI)1098-1004(1998)12:2&#x0003c;137::AID-HUMU15&#x0003e;3.0.CO;2-M</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Abdalla</surname><given-names>SA</given-names></name><name><surname>Cymerman</surname><given-names>U</given-names></name><name><surname>Johnson</surname><given-names>RM</given-names></name><name><surname>Deber</surname><given-names>CM</given-names></name><name><surname>Letarte</surname><given-names>M</given-names></name></person-group><article-title>Disease-associated mutations in conserved residues of ALK-1 kinase domain</article-title><source>Eur J Hum Genet</source><year>2003</year><volume>11</volume><fpage>279</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">12700602</pub-id><pub-id pub-id-type="doi">10.1038/sj.ejhg.5200919</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lesca</surname><given-names>G</given-names></name><name><surname>Plauchu</surname><given-names>H</given-names></name><name><surname>Coulet</surname><given-names>F</given-names></name><name><surname>Lefebvre</surname><given-names>S</given-names></name><name><surname>Plessis</surname><given-names>G</given-names></name><name><surname>Odent</surname><given-names>S</given-names></name><name><surname>Rivi&#x000e8;re</surname><given-names>S</given-names></name><name><surname>Leheup</surname><given-names>B</given-names></name><name><surname>Goizet</surname><given-names>C</given-names></name><name><surname>Carette</surname><given-names>MF</given-names></name><name><surname>Cordier</surname><given-names>JF</given-names></name><name><surname>Pinson</surname><given-names>S</given-names></name><name><surname>Soubrier</surname><given-names>F</given-names></name><name><surname>Calender</surname><given-names>A</given-names></name><name><surname>Giraud</surname><given-names>S</given-names></name><collab>French Rendu-Osler Network</collab></person-group><article-title>Molecular screening of ALK1/ACVRL1 and ENG genes in hereditary hemorrhagic telangiectasia in France</article-title><source>Hum Mutat</source><year>2004</year><volume>23</volume><fpage>289</fpage><lpage>99</lpage><pub-id pub-id-type="pmid">15024723</pub-id><pub-id pub-id-type="doi">10.1002/humu.20017</pub-id></citation></ref></ref-list></back></article> 